Nyxoah (NYXH)vsWest Pharmaceutical Services Inc (WST)
NYXH
Nyxoah
$3.17
-0.63%
HEALTHCARE · Cap: $137.97M
WST
West Pharmaceutical Services Inc
$247.02
+0.71%
HEALTHCARE · Cap: $17.68B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 54415% more annual revenue ($3.07B vs $5.64M). WST leads profitability with a 16.1% profit margin vs 0.0%. WST earns a higher WallStSmart Score of 55/100 (C-).
NYXH
Avoid29
out of 100
Grade: F
WST
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NYXH.
Margin of Safety
-256.8%
Fair Value
$68.99
Current Price
$247.02
$178.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 55.8% year-over-year
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Strong operational efficiency at 21.6%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
2.1% earnings growth
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NYXH
The strongest argument for NYXH centers on Revenue Growth, Price/Book. Revenue growth of 55.8% demonstrates continued momentum.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.
Bear Case : NYXH
The primary concerns for NYXH are EPS Growth, Market Cap, Profit Margin.
Bear Case : WST
The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.
Key Dynamics to Monitor
NYXH profiles as a hypergrowth stock while WST is a mature play — different risk/reward profiles.
WST carries more volatility with a beta of 1.18 — expect wider price swings.
NYXH is growing revenue faster at 55.8% — sustainability is the question.
WST generates stronger free cash flow (175M), providing more financial flexibility.
Bottom Line
WST scores higher overall (55/100 vs 29/100), backed by strong 16.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Nyxoah
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nyxoah is a pioneering medical technology firm specializing in the treatment of obstructive sleep apnea (OSA) through its innovative Genio system, which employs a minimally invasive hypoglossal nerve stimulation technique. The company is dedicated to enhancing patient outcomes and quality of life for those affected by OSA, backed by a strong commitment to clinical validation and research excellence. Nyxoah's strategic emphasis on technology advancement, complemented by partnerships and extensive studies, not only positions it to address significant unmet needs in the sleep medicine market but also underscores its potential for sustainable growth and transformative contributions to the healthcare industry.
Visit Website →West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?